drugset / Trial / NCT05581030
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calaspargase Pegol | Protein / enzyme biologic | 2000 unknown | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | — | — |